Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelyn Anton

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
JCO Oncology Practice|September 22, 2021
Global Disparity in Access to Novel Therapeutics for Metastatic Prostate CancerAngelyn Anton, Ben Tran
Frontiers in Oncology|December 24, 2024
The value of real world evidence and pragmatic trials in advanced prostate cancer- insights from the electronic Prostate Cancer Australian and Asian DatabaseAngelyn Anton, Kristina Zlatic, Sophie O'Haire, et al.
European Urology|January 11, 2025
…But Words Will Never Hurt MeIan D Davis, Angelyn Anton, Edmond M Kwan
Plos One|July 22, 2015
Increased Insulin following an Oral Glucose Load, Genetic Variation near the Melatonin Receptor MTNR1B, but No Biochemical Evidence of Endothelial Dysfunction in Young Asian Men and WomenMaria A Matuszek, Angelyn Anton, Sobana Thillainathan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 24, 2018
Exploring the spectrum of late effects following radical orchidectomy for stage I testicular seminoma: a systematic review of the literatureJennifer A Soon, Angelyn Anton, Javier Torres, et al.
JCO Oncology Practice|May 28, 2024
Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway InhibitorsYing Yan Zhong, Angelyn Anton, Owen Xie, et al.
Plos One|November 27, 2024
An immune suppressive tumor microenvironment in primary prostate cancer promotes tumor immune escapeAngelyn Anton, Ryan Hutchinson, Christopher M Hovens, et al.
Internal Medicine Journal|February 20, 2019
Impact of access to novel therapies on the initial management of castrate-resistant prostate cancer: an Australian multicentre studyEdmond M Kwan, Marie C Semira, Alice R T Bergin, et al.
BJUI Compass|September 17, 2025
Perioperative chemotherapy use and related outcomes in muscle-invasive bladder cancer in AustraliaAlison Hiong, James Lynam, Andrew Weickhardt, et al.
Asia-Pacific Journal of Clinical Oncology|January 31, 2022
Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysisGrace Chazan, Angelyn Anton, Shirley Wong, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
JCO Oncology Practice|September 22, 2021
Global Disparity in Access to Novel Therapeutics for Metastatic Prostate CancerAngelyn Anton, Ben Tran
Frontiers in Oncology|December 24, 2024
The value of real world evidence and pragmatic trials in advanced prostate cancer- insights from the electronic Prostate Cancer Australian and Asian DatabaseAngelyn Anton, Kristina Zlatic, Sophie O'Haire, et al.
European Urology|January 11, 2025
…But Words Will Never Hurt MeIan D Davis, Angelyn Anton, Edmond M Kwan
Plos One|July 22, 2015
Increased Insulin following an Oral Glucose Load, Genetic Variation near the Melatonin Receptor MTNR1B, but No Biochemical Evidence of Endothelial Dysfunction in Young Asian Men and WomenMaria A Matuszek, Angelyn Anton, Sobana Thillainathan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 24, 2018
Exploring the spectrum of late effects following radical orchidectomy for stage I testicular seminoma: a systematic review of the literatureJennifer A Soon, Angelyn Anton, Javier Torres, et al.
JCO Oncology Practice|May 28, 2024
Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway InhibitorsYing Yan Zhong, Angelyn Anton, Owen Xie, et al.
Plos One|November 27, 2024
An immune suppressive tumor microenvironment in primary prostate cancer promotes tumor immune escapeAngelyn Anton, Ryan Hutchinson, Christopher M Hovens, et al.
Internal Medicine Journal|February 20, 2019
Impact of access to novel therapies on the initial management of castrate-resistant prostate cancer: an Australian multicentre studyEdmond M Kwan, Marie C Semira, Alice R T Bergin, et al.
BJUI Compass|September 17, 2025
Perioperative chemotherapy use and related outcomes in muscle-invasive bladder cancer in AustraliaAlison Hiong, James Lynam, Andrew Weickhardt, et al.
Asia-Pacific Journal of Clinical Oncology|January 31, 2022
Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysisGrace Chazan, Angelyn Anton, Shirley Wong, et al.
Pageof 3